.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 7,052,679

« Back to Dashboard

Claims for Patent: 7,052,679

Title:Delivery of antipsychotics through an inhalation route
Abstract: The present invention relates to the delivery of antipsychotics through an inhalation route. Specifically, it relates to aerosols containing antipsychotics that are used in inhalation therapy. In a method aspect of the present invention, an antipsychotic is delivered to a patient through an inhalation route. The method comprises: a) heating a thin layer of an antipsychotic, on a solid support, to form a vapor; and, b) passing air through the heated vapor to produce aerosol particles having less than 5% antipsychotic drug degradation products. In a kit aspect of the present invention, a kit for delivering an antipsychotic through an inhalation route is provided which comprises: a) a thin film of an antipsychotic and b) a device for dispensing said thin film as a condensation aerosol.
Inventor(s): Rabinowitz; Joshua D. (Mountain View, CA), Zaffaroni; Alejandro C. (Atherton, CA)
Assignee: Alexza Pharmaceuticals, Inc. (Palo Alto, CA)
Application Number:10/767,115
Patent Claims: 1. A condensation aerosol for delivery of a drug selected from the group consisting of olanzapine, trifluoperazine, haloperidol, loxapine, risperidone, clozapine, quetiapine, promazine, thiothixene, chlorpromazine, droperidol, prochlorperazine and fluphenazine, wherein the condensation aerosol is formed by heating a thin layer containing the drug, on a solid support, to produce a vapor of the drug, and condensing the vapor to form a condensation aerosol, characterized by less than 10% drug degradation products by weight, and an MMAD of less than 5 microns.

2. The condensation aerosol according to claim 1, wherein the condensation aerosol is formed at a rate greater than 10.sup.9 particles per second.

3. The condensation aerosol according to claim 2, wherein the condensation aerosol is formed at a rate greater than 10.sup.10 particles per second.

4. A method of producing a drug selected from the group consisting of olanzapine, trifluoperazine, haloperidol, loxapine, risperidone, clozapine, quetiapine, promazine, thiothixene, chlorpromazine, droperidol, prochlorperazine and fluphenazine, in an aerosol form comprising: a. heating a thin layer containing the drug, on a solid support, to produce a vapor of the drug, and b. providing an air flow through the vapor to form a condensation aerosol characterized by less than 10% drug degradation products by weight, and an MMAD of less than 5 microns.

5. The method according to claim 4, wherein the condensation aerosol is formed at a rate greater than 10.sup.9 particles per second.

6. The method according to claim 5, wherein the condensation aerosol is formed at a rate greater than 10.sup.10 particles per second.

7. The condensation aerosol according to claim 1, wherein the condensation aerosol is characterized by an MMAD of 0.1 to 5 microns.

8. The condensation aerosol according to claim 1, wherein the condensation aerosol is characterized by an MMAD of less than 3 microns.

9. The condensation aerosol according to claim 1, wherein the condensation aerosol is characterized by an MMAD of about 0.2 to about 3 microns.

10. The condensation aerosol according to claim 1, wherein the condensation aerosol is characterized by less than 5% drug degradation products by weight.

11. The condensation aerosol according to claim 10, wherein the condensation aerosol is characterized by less than 2.5% drug degradation products by weight.

12. The condensation aerosol according to claim 1, wherein the solid support is a metal foil.

13. The condensation aerosol according to claim 1, wherein the drug is olanzapine.

14. The condensation aerosol according to claim 1, wherein the drug is trifluoperazine.

15. The condensation aerosol according to claim 1, wherein the drug is haloperidol.

16. The condensation aerosol according to claim 1, wherein the drug is loxapine.

17. The condensation aerosol according to claim 1, wherein the drug is risperidone.

18. The condensation aerosol according to claim 1, wherein the drug is clozapine.

19. The condensation aerosol according to claim 1, wherein the drug is quetiapine.

20. The condensation aerosol according to claim 1, wherein the drug is promazine.

21. The condensation aerosol according to claim 1, wherein the drug is thiothixene.

22. The condensation aerosol according to claim 1, wherein the drug is chlorpromazine.

23. The condensation aerosol according to claim 1, wherein the drug is droperidol.

24. The condensation aerosol according to claim 1, wherein the drug is prochlorperazine.

25. The condensation aerosol according to claim 1, wherein the drug is fluphenazine.

26. The method according to claim 4, wherein the condensation aerosol is characterized by an MMAD of 0.1 to 5 microns.

27. The method according to claim 4, wherein the condensation aerosol is characterized by an MMAD of less than 3 microns.

28. The method according to claim 4, wherein the condensation aerosol is characterized by an MMAD of about 0.2 to 3 microns.

29. The method according to claim 4, wherein the condensation aerosol is characterized by less than 5% drug degradation products by weight.

30. The method according to claim 29, wherein the condensation aerosol is characterized by less than 2.5% drug degradation products by weight.

31. The method according to claim 4, wherein the solid support is a metal foil.

32. The method according to claim 4, wherein the drug is olanzapine.

33. The method according to claim 4, wherein the drug is trifluoperazine.

34. The method according to claim 4, wherein the drug is haloperidol.

35. The method according to claim 4, wherein the drug is loxapine.

36. The method according to claim 4, wherein the drug is risperidone.

37. The method according to claim 4, wherein the drug is clozapine.

38. The method according to claim 4, wherein the drug is quetiapine.

39. The method according to claim 4, wherein the drug is promazine.

40. The method according to claim 4, wherein the drug is thiothixene.

41. The method according to claim 4, wherein the drug is chlorpromazine.

42. The method according to claim 4, wherein the drug is droperidol.

43. The method according to claim 4, wherein the drug is prochlorperazine.

44. The method according to claim 4, wherein the drug is fluphenazine.

45. A condensation aerosol for delivery of olanzapine, wherein the condensation aerosol is formed by heating a thin layer containing olanzapine, on a solid support, to produce a vapor of olanzapine, and condensing the vapor to form a condensation aerosol characterized by less than 5% olanzapine degradation products by weight, and an MMAD of 0.2 to 3 microns.

46. A condensation aerosol for delivery of trifluoperazine, wherein the condensation aerosol is formed by heating a thin layer containing trifluoperazine, on a solid support, to produce a vapor of trifluoperazine, and condensing the vapor to form a condensation aerosol characterized by less than 5% trifluoperazine degradation products by weight, and an MMAD of about 0.2 to 3 microns.

47. A condensation aerosol for delivery of haloperidol, wherein the condensation aerosol is formed by heating a thin layer containing haloperidol, on a solid support, to produce a vapor of haloperidol, and condensing the vapor to form a condensation aerosol characterized by less than 5% haloperidol degradation products by weight, and an MMAD of about 0.2 to 3 microns.

48. A condensation aerosol for delivery of loxapine, wherein the condensation aerosol is formed by heating a thin layer containing loxapine, on a solid support, to produce a vapor of loxapine, and condensing the vapor to form a condensation aerosol characterized by less than 5% loxapine degradation products by weight, and an MMAD of about 0.2 to 3 microns.

49. A condensation aerosol for delivery of risperidone, wherein the condensation aerosol is formed by heating a thin layer containing risperidone, on a solid support, to produce a vapor of risperidone, and condensing the vapor to form a condensation aerosol characterized by less than 5% risperidone degradation products by weight, and an MMAD of about 0.2 to 3 microns.

50. A condensation aerosol for delivery of clozapine, wherein the condensation aerosol is formed by heating a thin layer containing clozapine, on a solid support, to produce a vapor of clozapine, and condensing the vapor to form a condensation aerosol characterized by less than 5% clozapine degradation products by weight, and an MMAD of about 0.2 to 3 microns.

51. A condensation aerosol for delivery of quetiapine, wherein the condensation aerosol is formed by heating a thin layer containing quetiapine, on a solid support, to produce a vapor of quetiapine, and condensing the vapor to form a condensation aerosol characterized by less than 5% quetiapine degradation products by weight, and an MMAD of about 0.2 to 3 microns.

52. A condensation aerosol for delivery of promazine, wherein the condensation aerosol is formed by heating a thin layer containing promazine, on a solid support, to produce a vapor of promazine, and condensing the vapor to form a condensation aerosol characterized by less than 5% promazine degradation products by weight, and an MMAD of about 0.2 to 3 microns.

53. A condensation aerosol for delivery of thiothixene, wherein the condensation aerosol is formed by heating a thin layer containing thiothixene, on a solid support, to produce a vapor of thiothixene, and condensing the vapor to form a condensation aerosol characterized by less than 5% thiothixene degradation products by weight, and an MMAD of about 0.2 to 3 microns.

54. A condensation aerosol for delivery of chlorpromazine, wherein the condensation aerosol is formed by heating a thin layer containing chlorpromazine, on a solid support, to produce a vapor of chlorpromazine, and condensing the vapor to form a condensation aerosol characterized by less than 5% chlorpromazine degradation products by weight, and an MMAD of about 0.2 to 3 microns.

55. A condensation aerosol for delivery of droperidol, wherein the condensation aerosol is formed by heating a thin layer containing droperidol, on a solid support, to produce a vapor of droperidol, and condensing the vapor to form a condensation aerosol characterized by less than 5% droperidol degradation products by weight, and an MMAD of about 0.2 to 3 microns.

56. A condensation aerosol for delivery of prochlorperazine, wherein the condensation aerosol is formed by heating a thin layer containing prochlorperazine, on a solid support, to produce a vapor of prochlorperazine, and condensing the vapor to form a condensation aerosol characterized by less than 5% prochlorperazine degradation products by weight, and an MMAD of about 0.2 to 3 microns.

57. A condensation aerosol for delivery of fluphenazine, wherein the condensation aerosol is formed by heating a thin layer containing fluphenazine, on a solid support, to produce a vapor of fluphenazine, and condensing the vapor to form a condensation aerosol characterized by less than 5% fluphenazine degradation products by weight, and an MMAD of about 0.2 to 3 microns.

58. A method of producing olanzapine in an aerosol form comprising: a. heating a thin layer containing olanzapine, on a solid support, to produce a vapor of olanzapine, and b. providing an air flow through the vapor to form a condensation aerosol characterized by less than 5% olanzapine degradation products by weight, and an MMAD of about 0.2 to 3 microns.

59. A method of producing trifluoperazine in an aerosol form comprising: a. heating a thin layer containing trifluoperazine, on a solid support, to produce a vapor of trifluoperazine, and b. providing an air flow through the vapor to form a condensation aerosol characterized by less than 5% trifluoperazine degradation products by weight, and an MMAD of about 0.2 to 3 microns.

60. A method of producing haloperidol in an aerosol form comprising: a. heating a thin layer containing haloperidol, on a solid support, to produce a vapor of haloperidol, and b. providing an air flow through the vapor to form a condensation aerosol characterized by less than 5% haloperidol degradation products by weight, and an MMAD of about 0.2 to 3 microns.

61. A method of producing loxapine in an aerosol form comprising: a. heating a thin layer containing loxapine, on a solid support, to produce a vapor of loxapine, and b. providing an air flow through the vapor to form a condensation aerosol characterized by less than 5% loxapine degradation products by weight, and an MMAD of about 0.2 to 3 microns.

62. A method of producing risperidone in an aerosol form comprising: a. heating a thin layer containing risperidone, on a solid support, to produce a vapor of risperidone, and b. providing an air flow through the vapor to form a condensation aerosol characterized by less than 5% risperidone degradation products by weight, and an MMAD of about 0.2 to 3 microns.

63. A method of producing clozapine in an aerosol form comprising: a. heating a thin layer containing clozapine, on a solid support, to produce a vapor of clozapine, and b. providing an air flow through the vapor to form a condensation aerosol characterized by less than 5% clozapine degradation products by weight, and an MMAD of about 0.2 to 3 microns.

64. A method of producing quetiapine in an aerosol form comprising: a. heating a thin layer containing quetiapine, on a solid support, to produce a vapor of quetiapine, and b. providing an air flow through the vapor to form a condensation aerosol characterized by less than 5% quetiapine degradation products by weight, and an MMAD of about 0.2 to 3 microns.

65. A method of producing promazine in an aerosol form comprising: a. heating a thin layer containing promazine, on a solid support, to produce a vapor of promazine, and b. providing an air flow through the vapor to form a condensation aerosol characterized by less than 5% promazine degradation products by weight, and an MMAD of about 0.2 to 3 microns.

66. A method of producing thiothixene in an aerosol form comprising: a. heating a thin layer containing thiothixene, on a solid support, to produce a vapor of thiothixene, and b. providing an air flow through the vapor to form a condensation aerosol characterized by less than 5% thiothixene degradation products by weight, and an MMAD of about 0.2 to 3 microns.

67. A method of producing chlorpromazine in an aerosol form comprising: a. heating a thin layer containing chlorpromazine, on a solid support, to produce a vapor of chlorpromazine, and b. providing an air flow through the vapor to form a condensation aerosol characterized by less than 5% chlorpromazine degradation products by weight, and an MMAD of about 0.2 to 3 microns.

68. A method of producing droperidol in an aerosol form comprising: a. heating a thin layer containing droperidol, on a solid support, to produce a vapor of droperidol, and b. providing an air flow through the vapor to form a condensation aerosol characterized by less than 5% droperidol degradation products by weight, and an MMAD of about 0.2 to 3 microns.

69. A method of producing prochlorperazine in an aerosol form comprising: a. heating a thin layer containing prochlorperazine, on a solid support, to produce a vapor of prochlorperazine, and b. providing an air flow through the vapor to form a condensation aerosol characterized by less than 5% prochlorperazine degradation products by weight, and an MMAD of about 0.2 to 3 microns.

70. A method of producing fluphenazine in an aerosol form comprising: a. heating a thin layer containing fluphenazine, on a solid support, to produce a vapor of fluphenazine, and b. providing an air flow through the vapor to form a condensation aerosol characterized by less than 5% fluphenazine degradation products by weight, and an MMAD of about 0.2 to 3 microns.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc